Notably, by designing viral particles with anti-EGFR cetuximab and CCL5 chimeric receptors (OV-Cmab-CCL5), Tian and colleagues were additionally able to promote the specific infiltration of various immune cells to EGFR-positive GBM tumours [264]. The gene discussed is EGFR; the disease is neoplasm.